Valuation: Interpace Biosciences, Inc.

Market Cap 40.44M 35.51M 33.03M 30.31M 56.97M 3.9B 57.83M 392M 153M 1.91B 152M 149M 6.62B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 39.12M 34.35M 31.95M 29.32M 55.11M 3.78B 55.94M 379M 148M 1.85B 147M 144M 6.4B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
14.74%
Yield 2024 *
-
Yield 2025 -
1 day+2.29%
1 week+17.38%
Current month+9.82%
1 month+9.15%
3 months-9.37%
6 months+3.47%
Current year+45.50%
1 week 1.34
Extreme 1.34
1.79
1 month 1.34
Extreme 1.34
1.8
Current year 1.03
Extreme 1.03
2.4
1 year 0.77
Extreme 0.77
2.4
3 years 0.44
Extreme 0.4433
3.54
5 years 0.44
Extreme 0.4433
10.33
10 years 0.44
Extreme 0.4433
198
Manager TitleAgeSince
Chief Executive Officer 64 2020-11-30
Director of Finance/CFO 34 2023-04-20
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 2016-06-20
Director/Board Member 73 2015-12-31
Director/Board Member 64 2020-01-21
Date Insider Type Main position Quantity % Market Cap.
1/20/26
1315 Capital LLC
ConversionCompany 9,405,941 212.3938%
1/20/26
Ampersand Management LLC
ConversionCompany 13,861,386 313.0013%
2/1/24 Free

Chief Financial Officer

10,000 0.2314%
Change 5-day change 1-year change 3-year change Capi.($)
+2.29%+17.38%+98.87%-8.67% 40.44M
-1.02%-3.46%+88.62%+456.36% 37.52B
+1.98%+4.73%+12.01%+33.86% 24.34B
+2.02%-3.02%-24.40%-39.44% 7.33B
+0.97%-1.00%+7.25%+82.27% 4.84B
+4.27%+4.26%+14.34%+47.64% 3.05B
-2.46%-4.93%+120.83%-16.53% 1.81B
-2.07%-1.52%-14.29%-63.84% 1.78B
-6.75%-6.90%-25.97%+695.42% 1.75B
+5.58%-1.99%+12.29%+2.91% 1.74B
Average +0.48%-1.50%+28.95%+119.00% 8.42B
Weighted average by Cap. +0.38%-0.69%+43.82%+229.00%

Financials

2024 2025
Net sales 46.93M 41.2M 38.32M 35.16M 66.1M 4.53B 67.1M 454M 178M 2.22B 176M 172M 7.68B 38.73M 34M 31.63M 29.02M 54.55M 3.74B 55.38M 375M 147M 1.83B 145M 142M 6.34B
Net income 6.7M 5.88M 5.47M 5.02M 9.44M 647M 9.58M 64.91M 25.39M 317M 25.15M 24.61M 1.1B 24.58M 21.58M 20.07M 18.42M 34.62M 2.37B 35.14M 238M 93.1M 1.16B 92.22M 90.26M 4.02B
Net Debt 4.4M 3.86M 3.59M 3.29M 6.19M 424M 6.28M 42.56M 16.65M 208M 16.49M 16.14M 719M -1.32M -1.16M -1.08M -991K -1.86M -128M -1.89M -12.8M -5.01M -62.55M -4.96M -4.86M -216M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
26-07-24 $1.460 +0.69% 4,002
26-07-23 $1.450 -3.97% 2,536
26-07-22 $1.510 +0.37% 4,632
26-07-21 $1.504 +0.97% 1,217
26-07-20 $1.490 -2.30% 4,423

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG Stock